Industry

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety … [Read more…]

The largest annual optics and photonics event of the year highlighted exciting new research, networking, and the latest in photonics products and industry trends BELLINGHAM, Wash.–(BUSINESS WIRE)–SPIE, the international society for optics and photonics, registered 24,000 optics and photonics professionals from over 75 countries for Photonics West, as the Society hosted the largest international annual … [Read more…]

The documentary will feature Unite Us’ ground-breaking collaboration platform that’s revolutionizing the way social care is delivered, demonstrating Unite Us’ proven effectiveness by showcasing its partnership with North Carolina’s Healthy Opportunities Pilot program. NEW YORK–(BUSINESS WIRE)–#HealthcareInnovation–Unite Us, the nation’s leading technology partner for social care transformation, will be featured in an upcoming segment on Viewpoint … [Read more…]

TUSTIN, Calif.–(BUSINESS WIRE)–Veterinary Surgical Specialists of Orange County (VSSOC), a leader in advanced veterinary surgical care since 1990, is proud to announce the opening of its new, state-of-the-art Surgery Center located at 2937 Edinger Avenue, Tustin, CA, just a few doors down from its flagship hospital. VSSOC provides a wide range of progressive surgical services, … [Read more…]

Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate With these data, Breyanzi demonstrates efficacy and manageable safety in a fifth cancer type, the most of any CD19-directed CAR T cell therapy PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Breyanzi—Bristol Myers Squibb (NYSE: BMY) today announced the Phase 2 TRANSCEND FL trial … [Read more…]

Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit) Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing … [Read more…]

TOKYO & TORONTO–(BUSINESS WIRE)–PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products. This joint initiative will integrate “LiCellGrowTM(*2), PHC’s cell expansion system under development, with CCRM’s deep knowledge … [Read more…]

OCHU-CUPE to hold media conference outside Bracebridge Hospital on Monday at 10:00 a.m. BRACEBRIDGE, Ontario–(BUSINESS WIRE)–On the eve of the provincial election, a line-up of hospital stretchers outside Bracebridge Hospital will symbolize the crisis in Ontario’s health care: – 1,860 people on stretchers in hospital hallways, up from 826 in June 2018 when the Premier … [Read more…]

GHLF Urges Greater Transparency and Patient Protections UPPER NYACK, N.Y.–(BUSINESS WIRE)–The Global Healthy Living Foundation (GHLF), a leading worldwide patient advocacy organization, is raising concerns about the lack of full disclosure in the Hims & Hers Health Super Bowl ad to be aired tomorrow night. The ad promotes, without identifying, semaglutide, the compounded versions of … [Read more…]

SAN FRANCISCO & SHANGHAI–(BUSINESS WIRE)–AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data from its ongoing Phase 2 clinical study of AL01211 in treatment-naïve, classic male Fabry disease patients. These findings were highlighted in a late-breaking oral platform presentation at the 2025 WORLD Symposium in San Diego, … [Read more…]